The preclinical data suggests the hypothesis that inhibitory GIPR + neurons act specifically on GLP-1R+ neurons that drive nausea and food aversion or avoidance to dampen GLP-1R mediated nausea without reducing efficacy, potentially lifting the ceiling of GLP-1R agonist-induced reductions in body weight. This evidence concerns the gene GIPR and Nausea.